Tuija Huusko1, Tuire Salonurmi2, Panu Taskinen3, Johanna Liinamaa4, Tatu Juvonen3, Paavo Pääkkö5, Markku Savolainen2, Sakari Kakko2. 1. Institute of Clinical Medicine, Department of Internal Medicine, Clinical Research Center, Oulu University Hospital and Biocenter Oulu, University of Oulu, Oulu, Finland. Electronic address: tuija.huusko@oulu.fi. 2. Institute of Clinical Medicine, Department of Internal Medicine, Clinical Research Center, Oulu University Hospital and Biocenter Oulu, University of Oulu, Oulu, Finland. 3. Institute of Clinical Medicine, Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland. 4. Department of Ophthalmology, Institute of Clinical Medicine, Oulu University Hospital and University of Oulu, Oulu, Finland. 5. Institute of Diagnostics, Department of Pathology, Oulu University Hospital and University of Oulu, Oulu, Finland.
Abstract
OBJECTIVE: Ascending aortic aneurysms result from a degenerative process in the aortic wall, characterized by the loss of smooth muscle cells and elastic fibers. We hypothesized that there would be changes in plasma protein and aortic tissue messenger RNA levels of osteopontin, matrix metalloproteinase type 2, matrix metalloproteinase type 9, and tissue inhibitor of matrix metalloproteinases type 1 in ascending aortic aneurysm samples. METHODS: Plasma, aortic tissue, and aortic mRNA samples were collected from patients with an ascending aortic aneurysm or an abdominal aortic aneurysm and from control individuals. Plasma protein levels of osteopontin, matrix metalloproteinase (MMP) types 2 and 9, and tissue inhibitor of matrix metalloproteinases type 1 were determined by quantitative sandwich enzyme-linked immunosorbent assay. Aortic mRNA levels of these same proteins were analyzed with the quantitative real-time polymerase chain reaction (RT-PCR) method and protein levels from the aortic tissues were assayed by immunostaining. Quantitative RT-PCR results were estimated by the normalized expression method (ΔΔCt). RESULTS: Plasma protein levels were significantly elevated for osteopontin, MMP-2, and MMP-9 in the samples of ascending and abdominal aortic aneurysm group compared with controls. Plasma protein levels of MMP-9 were higher in the nonoperated compared with the operated ascending aortic aneurysm group. Aortic osteopontin, MMP-2, and MMP-9 mRNA levels were increased for ascending aortic aneurysm samples. CONCLUSIONS: This study reveals an important role of osteopontin, MMP-2 and MMP-9 in the development of ascending and abdominal aortic aneurysm.
OBJECTIVE: Ascending aortic aneurysms result from a degenerative process in the aortic wall, characterized by the loss of smooth muscle cells and elastic fibers. We hypothesized that there would be changes in plasma protein and aortic tissue messenger RNA levels of osteopontin, matrix metalloproteinase type 2, matrix metalloproteinase type 9, and tissue inhibitor of matrix metalloproteinases type 1 in ascending aortic aneurysm samples. METHODS: Plasma, aortic tissue, and aortic mRNA samples were collected from patients with an ascending aortic aneurysm or an abdominal aortic aneurysm and from control individuals. Plasma protein levels of osteopontin, matrix metalloproteinase (MMP) types 2 and 9, and tissue inhibitor of matrix metalloproteinases type 1 were determined by quantitative sandwich enzyme-linked immunosorbent assay. Aortic mRNA levels of these same proteins were analyzed with the quantitative real-time polymerase chain reaction (RT-PCR) method and protein levels from the aortic tissues were assayed by immunostaining. Quantitative RT-PCR results were estimated by the normalized expression method (ΔΔCt). RESULTS: Plasma protein levels were significantly elevated for osteopontin, MMP-2, and MMP-9 in the samples of ascending and abdominal aortic aneurysm group compared with controls. Plasma protein levels of MMP-9 were higher in the nonoperated compared with the operated ascending aortic aneurysm group. Aortic osteopontin, MMP-2, and MMP-9 mRNA levels were increased for ascending aortic aneurysm samples. CONCLUSIONS: This study reveals an important role of osteopontin, MMP-2 and MMP-9 in the development of ascending and abdominal aortic aneurysm.
Authors: Ayman A Saeyeldin; Camilo A Velasquez; Syed Usman B Mahmood; Adam J Brownstein; Mohammad A Zafar; Bulat A Ziganshin; John A Elefteriades Journal: Gen Thorac Cardiovasc Surg Date: 2017-12-04
Authors: Minako Ishibashi; Scott Sayers; Jeanine M D'Armiento; Alan R Tall; Carrie L Welch Journal: Atherosclerosis Date: 2013-04-09 Impact factor: 5.162
Authors: Anke Tscheuschler; Philipp Meffert; Friedhelm Beyersdorf; Claudia Heilmann; Nadja Kocher; Xenia Uffelmann; Philipp Discher; Matthias Siepe; Fabian A Kari Journal: PLoS One Date: 2016-11-01 Impact factor: 3.240
Authors: Sergio Prieto-González; Nekane Terrades-García; Marc Corbera-Bellalta; Ester Planas-Rigol; Chie Miyabe; Marco A Alba; Ariel Ponce; Itziar Tavera-Bahillo; Giuseppe Murgia; Georgina Espígol-Frigolé; Javier Marco-Hernández; José Hernández-Rodríguez; Ana García-Martínez; Sebastian H Unizony; Maria C Cid Journal: RMD Open Date: 2017-12-22
Authors: Tuija J Huusko; Merja Santaniemi; Sakari Kakko; Panu Taskinen; Olavi Ukkola; Y Antero Kesäniemi; Markku J Savolainen; Tuire Salonurmi Journal: PLoS One Date: 2012-11-29 Impact factor: 3.240